Zobrazeno 1 - 10
of 98
pro vyhledávání: '"David C. Lowe"'
Autor:
Elizabeth England, D. Gareth Rees, Ian Christopher Scott, Sara Carmen, Denice T. Y. Chan, Catherine E. Chaillan Huntington, Kirsty F. Houslay, Teodor Erngren, Mark Penney, Jayesh B. Majithiya, Laura Rapley, Dorothy A. Sims, Claire Hollins, Elizabeth C. Hinchy, Martin D. Strain, Benjamin P. Kemp, Dominic J. Corkill, Richard D. May, Katherine A. Vousden, Robin J. Butler, Tomas Mustelin, Tristan J. Vaughan, David C. Lowe, Caroline Colley, E. Suzanne Cohen
Publikováno v:
Scientific Reports, Vol 13, Iss 1, Pp 1-15 (2023)
Abstract Interleukin (IL)-33 is a broad-acting alarmin cytokine that can drive inflammatory responses following tissue damage or infection and is a promising target for treatment of inflammatory disease. Here, we describe the identification of tozora
Externí odkaz:
https://doaj.org/article/4d1e1f2da3f148aa85e1df6a32f0ef69
Autor:
Jessica S. Ebo, Janet C. Saunders, Paul W. A. Devine, Alice M. Gordon, Amy S. Warwick, Bob Schiffrin, Stacey E. Chin, Elizabeth England, James D. Button, Christopher Lloyd, Nicholas J. Bond, Alison E. Ashcroft, Sheena E. Radford, David C. Lowe, David J. Brockwell
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-12 (2020)
Protein aggregation remains a significant challenge for manufacturing of protein biopharmaceuticals. Here, the authors demonstrate the use of directed evolution and an assay for in vivo innate protein aggregation-propensity to generate aggregation-re
Externí odkaz:
https://doaj.org/article/7cd4d27ccee2435a841e247a296e334c
Autor:
Elizabeth England, D. Gareth Rees, Ian Christopher Scott, Sara Carmen, Denice T. Y. Chan, Catherine E. Chaillan Huntington, Kirsty F. Houslay, Teodor Erngren, Mark Penney, Jayesh B. Majithiya, Laura Rapley, Dorothy A. Sims, Claire Hollins, Elizabeth C. Hinchy, Martin D. Strain, Benjamin P. Kemp, Dominic J. Corkill, Richard D. May, Katherine A. Vousden, Robin J. Butler, Tomas Mustelin, Tristan J. Vaughan, David C. Lowe, Caroline Colley, E. Suzanne Cohen
Interleukin (IL)-33 is a broad-acting alarmin cytokine that can drive inflammatory responses following tissue damage or infection and is a promising target for treatment of inflammatory disease. Here, we describe the identification of tozorakimab (ME
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2623b7a64721c16cead1782c6553f513
https://doi.org/10.1101/2023.02.28.527262
https://doi.org/10.1101/2023.02.28.527262
Autor:
Paul W. A. Devine, Elizabeth England, Nicholas J. Bond, David C. Lowe, Amy S. Warwick, James Button, Sheena E. Radford, Janet C. Saunders, Bob Schiffrin, Alison E. Ashcroft, Alice M. Gordon, Chris Lloyd, David J. Brockwell, Stacey E. Chin, Jessica S. Ebo
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-12 (2020)
Nature Communications
Nature Communications
Protein biopharmaceuticals are highly successful, but their utility is compromised by their propensity to aggregate during manufacture and storage. As aggregation can be triggered by non-native states, whose population is not necessarily related to t
Autor:
David C. Lowe, Alison E. Ashcroft, Daniel R. Higazi, Paul W. A. Devine, Antonio N. Calabrese, Jennifer R. Potts, Fiona Whelan, Henry C. Fisher, Sheena E. Radford
Publikováno v:
Journal of the American Society for Mass Spectrometry
Collision cross-section (CCS) measurements obtained from ion mobility spectrometry-mass spectrometry (IMS-MS) analyses often provide useful information concerning a protein’s size and shape and can be complemented by modeling procedures. However, t
Autor:
Nicole Burmeister, Tristan J. Vaughan, Matthieu Chodorge, Laura Mitchell, John Andrews, Andrew Buchanan, David C. Lowe, Alistair D. Kippen, Daniel R. Higazi, Jonathan J. Phillips, Sudharsan Sridharan
Publikováno v:
Analytical Chemistry. 89:2361-2368
Antibodies are an important class of drugs, comprising more than half of all new FDA approvals. Therapeutic antibodies must be chemically stable both in storage and in vivo, following administration to patients. Deamidation is a major degradation pat
Autor:
Matthew A. Sleeman, Philip Newton, Brian Naiman, Katherine A. Vousden, Anja Pomowski, James A. Huntington, Clare Murray, Isabelle de Mendez, Tristan J. Vaughan, Alan M. Carruthers, Jane Connor, Daniel J. D. Johnson, Strain Martin D, Patrick Dufner, Tomas Lundqvist, Trevor Wilkinson, Philip R. Mallinder, Bojana Popovic, Lynne Murray, David C. Lowe
Publikováno v:
Scientific Reports
Scientific Reports, Vol 9, Iss 1, Pp 1-12 (2019)
'Scientific Reports ', vol: 9, pages: 1605-1-1605-12 (2019)
Scientific Reports, Vol 9, Iss 1, Pp 1-12 (2019)
'Scientific Reports ', vol: 9, pages: 1605-1-1605-12 (2019)
Plasminogen activator inhibitor-1 (PAI-1) is a serine protease inhibitor (serpin) that regulates fibrinolysis, cell adhesion and cell motility via its interactions with plasminogen activators and vitronectin. PAI-1 has been shown to play a role in a
Autor:
Sebastian Spindeldreher, Mark Austin, Carl I. Webster, David C. Lowe, Matthew P. Baker, Tim Jones, Christine J. Bryson, Edward A. Cloake, Anette Karle
Publikováno v:
mAbs
The immunogenicity of clinically administered antibodies has clinical implications for the patients receiving them, ranging from mild consequences, such as increased clearance of the drug from the circulation, to life-threatening effects. The emergen
Autor:
David C. Lowe, Jonathan J. Phillips, Daniel R. Higazi, Alistair D. Kippen, James H. Scrivens, Matthew Edgeworth
Publikováno v:
Angewandte Chemie. 127:15371-15374
Immunoglobulin G (IgG) monoclonal antibodies (mAbs) are a major class of medicines, with high specificity and affinity towards targets spanning many disease areas. The antibody Fc (fragment crystallizable) region is a vital component of existing anti
Autor:
David C. Lowe, Lutz Jermutus, Daniel Christ, Tri Giang Phan, Rodrigo Vazquez-Lombardi, Carsten Zimmermann
Publikováno v:
Drug Discovery Today. 20:1271-1283
The first candidates from the promising class of small non-antibody protein scaffolds are now moving into clinical development and practice. Challenges remain, and scaffolds will need to be further tailored toward applications where they provide real